Literature DB >> 12665307

Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours.

Jinghai Sun1, Ivana Cecic, Charles S Parkins, Mladen Korbelik.   

Abstract

Neutrophils have become recognised as important contributors to the effectiveness of tumour eradication by photodynamic therapy (PDT). In this study, we have used the mouse SCCVII squamous cell carcinoma model to investigate the activity of neutrophils in tumours treated by PDT. Tumour levels of neutrophilic myeloperoxidase (MPO) demonstrated not only a massive and sustained sequestration of these cells in PDT-treated tumours but also revealed their activated state evidenced by the presence of released MPO. Among the adhesion molecules expressed on tumour vascular endothelium, ICAM-1 appears to be of primary importance in the invasion of neutrophils into PDT-treated tumours, because its functional blocking with monoclonal antibodies reduced the tumour cure rate. A marked upregulation of its ligands CD11b/CD18 and CD11c/CD18 found on neutrophils associated with PDT-treated tumours supports this assumption. To evaluate the role of inflammatory cytokines regulating neutrophil activity, neutralising antibodies were given to mice before PDT treatment. The results suggest that IL-1beta activity is critical for the therapeutic outcome, since its neutralisation diminished the cure rates of PDT-treated tumours. No significant effect was observed with anti-IL-6 and anti-TNF-alpha treatment. Further flow cytometry-based examination of neutrophils round in PDT-treated tumours revealed that these cells express MHC class II molecules, which suggests their engagement as antigen-presenting cells and involvement in the development of antitumour immune response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12665307     DOI: 10.1039/b204254a

Source DB:  PubMed          Journal:  Photochem Photobiol Sci        ISSN: 1474-905X            Impact factor:   3.982


  28 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

2.  Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response.

Authors:  D Separovic; J Bielawski; J S Pierce; S Merchant; A L Tarca; G Bhatti; B Ogretmen; M Korbelik
Journal:  Int J Oncol       Date:  2010-12-06       Impact factor: 5.650

Review 3.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

4.  Photodynamic therapy using intra-articular Photofrin for murine MRSA arthritis: biphasic light dose response for neutrophil-mediated antibacterial effect.

Authors:  Masamitsu Tanaka; Manabu Kinoshita; Yasuo Yoshihara; Nariyoshi Shinomiya; Shuhji Seki; Koichi Nemoto; Michael R Hamblin; Yuji Morimoto
Journal:  Lasers Surg Med       Date:  2011-03       Impact factor: 4.025

5.  Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy.

Authors:  Richard W Davis; Emma Snyder; Joann Miller; Shirron Carter; Cassandra Houser; Astero Klampatsa; Steven M Albelda; Keith A Cengel; Theresa M Busch
Journal:  Photochem Photobiol       Date:  2018-11-26       Impact factor: 3.421

6.  Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2005-03       Impact factor: 3.631

Review 7.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

8.  Intratumor administration of the photosensitizer pc 4 affords photodynamic therapy efficacy and selectivity at short drug-light intervals.

Authors:  Thomas H Foster; Benjamin R Giesselman; Rui Hu; Malcolm E Kenney; Soumya Mitra
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

9.  IL-6 potentiates tumor resistance to photodynamic therapy (PDT).

Authors:  Craig M Brackett; Barbara Owczarczak; Kimberley Ramsey; Patricia G Maier; Sandra O Gollnick
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

10.  Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas.

Authors:  D Separovic; J Bielawski; J S Pierce; S Merchant; A L Tarca; B Ogretmen; M Korbelik
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.